PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
RNA-seq data from human cancer cell lines treated with PRMT5 inhibitor C220 (PRT220).